Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RVT-602

- PMLiVE

Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer

The approval for the treatment applies to England, Scotland and Wales

- PMLiVE

FDA approves Bot Image’s AI software for the detection and diagnosis of prostate cancer

ProstateID combines artificial intelligence with traditional MRI scanning to significantly improve radiologic interpretation accuracy

- PMLiVE

Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy

Around 200 million women suffer from endometriosis worldwide and it can take between four to eleven years to get a diagnosis

- PMLiVE

Takeda and Daiichi Sankyo collaborate to create wearable device

Takeda and Daiichi Sankyo have announced that they will work on a new research project, along with Tohoku University and MICIN, a digital health and telemedicine company, to develop a...

- PMLiVE

How marketers are balancing the changing trends in women’s health

We’ve reached a turning point in the way we view and provide healthcare to women. In the midst of discontent with the way that women are treated in healthcare and...

IGNIFI

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

The power of influence in transforming women’s health

Over the past four years HRT prescriptions have doubled in the UK, the cause was turbo charged by the action of celebrities and influencers.

Say Communications

Thrive webinar on women's health and tech panel discussion

Bridging the gender health gap: 9 key takeaways from Thrive’s webinar on tech and women’s health

Unequal health outcomes have been a reality for women throughout the world for far too long. But change is finally happening.

Thrive Agency

Takeda agrees on $2bn deal with Code Bio to expand its gene therapy programmes

The pharma company will gain opt-in rights for four rare diseases candidates

- PMLiVE

Could femtech be the answer to the gender health gap?

Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...

IGNIFI

- PMLiVE

Women’s 2021 health wins worth celebrating

Women’s health came under fresh scrutiny in 2021 as moves were made to close the gender health gap in the UK. But what were the key wins that have helped...

Thrive Agency

- PMLiVE

FDA rejects Takeda’s Eohilia after delays

After more than a year on ‘priority review’, the FDA has said it cannot approve Takeda’s budesonide oral suspension without a further clinical study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links